Search

Your search keyword '"ARANDA, Ignacio"' showing total 139 results
Start Over Author "ARANDA, Ignacio"
139 results on '"ARANDA, Ignacio"'

1. RET Fusion Testing in Patients With NSCLC: The RETING Study

Author

Conde, Esther, Hernandez, Susana, Rodriguez Carrillo, Jose Luis, Martinez, Rebeca, Alonso, Marta, Curto, Daniel, Jimenez, Beatriz, Caminoa, Alejandra, Benito, Amparo, Garrido, Pilar, Clave, Sergi, Arriola, Edurne, Esteban-Rodriguez, Isabel, De Castro, Javier, Sansano, Irene, Felip, Enriqueta, Rojo, Federico, Dómine, Manuel, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Teixido, Cristina, Reguart, Noemi, Compañ, Desamparados, Insa, Amelia, Mancheño, Nuria, Palanca, Sarai, Juan-Vidal, Oscar, Baixeras, Nuria, Nadal, Ernest, Cebollero, Maria, Calles, Antonio, Martin, Paloma, Salas, Clara, Provencio, Mariano, Aranda, Ignacio, Massuti, Bartomeu, Lopez-Vilaro, Laura, Majem, Margarita, Paz-Ares, Luis, and Lopez-Rios, Fernando

Published
2024
Full Text
View/download PDF

2. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

Author

Conde, Esther, Hernandez, Susana, Martinez, Rebeca, Angulo, Barbara, De Castro, Javier, Collazo-Lorduy, Ana, Jimenez, Beatriz, Muriel, Alfonso, Mate, Jose Luis, Moran, Teresa, Aranda, Ignacio, Massuti, Bartomeu, Rojo, Federico, Domine, Manuel, Sansano, Irene, Garcia, Felip, Felip, Enriqueta, Mancheño, Nuria, Juan, Oscar, Sanz, Julian, Gonzalez-Larriba, Jose Luis, Atienza-Cuevas, Lidia, Arriola-Arellano, Esperanza, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Camacho, Carmen, Rodriguez-Abreu, Delvys, Teixido, Cristina, Reguart, Noemi, Gonzalez-Piñeiro, Ana, Lazaro-Quintela, Martin, Lozano, Maria Dolores, Gurpide, Alfonso, Gomez-Roman, Javier, Lopez-Brea, Marta, Pijuan, Lara, Salido, Marta, Arriola, Edurne, Company, Amparo, Insa, Amelia, Esteban-Rodriguez, Isabel, Saiz, Monica, Azkona, Eider, Alvarez, Ramiro, Artal, Angel, Plaza, Maria Luz, Aguiar, David, Enguita, Ana Belen, Benito, Amparo, Paz-Ares, Luis, Garrido, Pilar, and Lopez-Rios, Fernando

Published
2019
Full Text
View/download PDF

6. Thermal Properties and In Vitro Biodegradation of PLA-Mg Filaments for Fused Deposition Modeling

Author

Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), European Commission, Leonés, Adrián [0000-0002-6590-1024], Salaris, Valentina [0000-0003-4532-874X], Lieblich, Marcela [0000-0003-1887-1480], López, Daniel [0000-0001-6386-5798], Peponi, Laura [0000-0001-6542-091X], Leonés, Adrián, Salaris, Valentina, Ramos Aranda, Ignacio, Lieblich, Marcela, López García, Daniel, Peponi, Laura, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), European Commission, Leonés, Adrián [0000-0002-6590-1024], Salaris, Valentina [0000-0003-4532-874X], Lieblich, Marcela [0000-0003-1887-1480], López, Daniel [0000-0001-6386-5798], Peponi, Laura [0000-0001-6542-091X], Leonés, Adrián, Salaris, Valentina, Ramos Aranda, Ignacio, Lieblich, Marcela, López García, Daniel, and Peponi, Laura

Abstract

Additive manufacturing, in particular the fused deposition method, is a quite new interesting technique used to obtain specific 3D objects by depositing layer after layer of material. Generally, commercial filaments can be used in 3D printing. However, the obtention of functional filaments is not so easy to reach. In this work, we obtain filaments based on poly(lactic acid), PLA, reinforced with different amounts of magnesium, Mg, microparticles, using a two-step extrusion process, in order to study how processing can affect the thermal degradation of the filaments; we additionally study their in vitro degradation, with a complete release of Mg microparticles after 84 days in phosphate buffer saline media. Therefore, considering that we want to obtain a functional filament for further 3D printing, the simpler the processing, the better the result in terms of a scalable approach. In our case, we obtain micro-composites via the double-extrusion process without degrading the materials, with good dispersion of the microparticles into the PLA matrix without any chemical or physical modification of the microparticles.

Published
2023

7. Pathological Findings Associated With SARS-CoV-2 on Postmortem Core Biopsies: Correlation With Clinical Presentation and Disease Course

Author

Ramos-Rincon, Jose-Manuel, primary, Herrera-García, Cristian, additional, Silva-Ortega, Sandra, additional, Portilla-Tamarit, Julia, additional, Alenda, Cristina, additional, Jaime-Sanchez, Francisco-Angel, additional, Arenas-Jiménez, Juan, additional, Fornés-Riera, Francisca-Eugenia, additional, Scholz, Alexander, additional, Escribano, Isabel, additional, Pedrero-Castillo, Víctor, additional, Muñoz-Miguelsanz, Carlos, additional, Orts-Llinares, Pedro, additional, Martí-Pastor, Ana, additional, Amo-Lozano, Antonio, additional, García-Sevila, Raquel, additional, Ribes-Mengual, Isabel, additional, Moreno-Perez, Oscar, additional, Concepcion-Aramendía, Luis, additional, Merino, Esperanza, additional, Sánchez-Martínez, Rosario, additional, and Aranda, Ignacio, additional

Published
2022
Full Text
View/download PDF

10. Validation of a clinicopathological classification for the prediction of pituitary adenomas: a retrospective cohort study in a PTCOE from 2013 to 2020

Author

Arguello, Gordillo Thalia, primary, Miguel, Castro Garcia Jose, additional, Martinez, Gauffin Lucia, additional, Kuptsov, Artem, additional, Tejedo-Flors, Dolores, additional, Eugenia, Torregrosa-Quesada Maria, additional, Abarca, Olivas Javier, additional, Concepcion, Luis, additional, Aranda, Ignacio, additional, and Pico, Antonio, additional

Published
2022
Full Text
View/download PDF

12. Adjuvant docetaxel for high-risk, node-negative breast cancer

Author

Martin, Miguel, Segui, Miguel A., Anton, Antonio, Ruiz, Amparo, Ramos, Manuel, Adrover, Encarna, Aranda, Ignacio, Rodriguez-Lescure, Alvaro, Grobe, Regina, Calvo, Lourdes, Barnadas, Agusti, Isla, Dolores, del Prado, Purification Martinez, Borrego, Manuel Ruiz, Zaluski, Jerzy, Arcusa, Angels, Munoz, Montserrat, Vega, Jose M. Lopez, Mel, Jose R., Munarriz, Blanca, Llorca, Cristina, Jara, Carlos, Alba, Emilio, Florian, Jesus, Junfang Li, Garcia-Asenjo, Jose A. Lopez, Saez, Amparo, Rios, Maria Jose, Almenar, Sergio, Peiro, Gloria, and Lluch, Ana

Subjects
Breast cancer -- Risk factors, Breast cancer -- Drug therapy, Docetaxel -- Health aspects, Doxorubicin -- Health aspects, Cyclophosphamide -- Health aspects, Fluorouracil -- Health aspects, Cancer -- Adjuvant treatment, Cancer -- Patient outcomes
Abstract

A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is shown to be superior to a regimen of fluorouracil, doxorubicin and cyclophosphamide (FAC) when they are used as adjuvant therapy in women with node-positive breast cancer. The studies have shown that when compared with adjuvant FAC, adjuvant TAC has improved the rate of disease-free survival among women with high-risk, node-negative breast cancer.

Published
2010

14. Histopathological and virological features of lung, heart and liver percutaneous tissue core biopsy in patients with COVID-19: A clinicopathological case series.

Author

RAMOS-RINCON, Jose-Manuel, ALENDA, Cristina, GARCÍA-SEVILA, Raquel, SILVA-ORTEGA, Sandra, GARCÍA-NAVARRO, Mar, VIDAL, Inmaculada, RIBES, Isabel, PORTILLA, Julia, CINTAS, Alejandro, MORENO-PÉREZ, Oscar, SÁNCHEZ-MARTÍNEZ, Rosario, MERINO, Esperanza, and ARANDA, Ignacio

Abstract

Introduction: Data on pathological changes in COVID-19 are scarce. The aim of this study was to describe the histopathological and virological findings of postmortem biopsies, and the existing clinical correlations, in people who died of COVID-19. Materials and Methods: We performed postmortem needle core biopsies of the chest in 11 people who died of COVID-19 pneumonia. Tissue examination was done by light microscopy and real-time polymerase chain reaction (RTPCR). Results: The age of the patients were between 61 to 94 years. Of the 11 postmortem chest biopsies, lung tissue was obtained in 8, myocardium tissue in 7, and liver tissue in 5. Histologically of lung, the main findings pertaining to the lung were diffuse alveolar damage in proliferative phase (n = 4, 50%), diffuse alveolar damage in exudative and proliferative phase (n = 3, 37.5%), diffuse alveolar damage in exudative (n=1; 12.5%) and acute pneumonia (n = 2, 25%). Necrotising pneumonia, acute fibrinous and organising pneumonia, and neutrophils were detected in one sample each (12.5%). Another case presented myocarditis. RT-PCR showed RNA of SARS-CoV-2 in 7 of the 8 lung samples (87.5%), 2 of the 7 myocardial tissue samples (28.6%), and 1 of the 5 liver tissue samples (20%). Conclusion: The postmortem examinations show diffuse alveolar damage, as well as acute or necrotising pneumonia. RT-PCR of SARS-CoV-2 was positive in most lung samples. [ABSTRACT FROM AUTHOR]

Published
2022

16. New advances in the diagnosis of gonadotroph tumours

Author

García-Martínez, Araceli, primary, Morote-Guillén, Cristina, additional, Martínez-López, Sebastián, additional, Eugenia, Torregrosa-Quesada María, additional, Silva-Ortega, Sandra, additional, López-Muñoz, Beatriz, additional, Moreno, Óscar, additional, Aranda, Ignacio, additional, and Picó, Antonio, additional

Published
2020
Full Text
View/download PDF

20. How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria?

Author

Torregrosa-Quesada, María Eugenia, primary, García-Martínez, Araceli, additional, Silva-Ortega, Sandra, additional, Martínez-López, Sebastián, additional, Cámara, Rosa, additional, Fajardo, Carmen, additional, Lamas, Cristina, additional, Aranda, Ignacio, additional, and Picó, Antonio, additional

Published
2019
Full Text
View/download PDF

28. PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

Author

Bastien Roy RL, Rodríguez-Lescure Álvaro, Ebbert Mark TW, Prat Aleix, Munárriz Blanca, Rowe Leslie, Miller Patricia, Ruiz-Borrego Manuel, Anderson Daniel, Lyons Bradley, Álvarez Isabel, Dowell Tracy, Wall David, Seguí Miguel, Barley Lee, Boucher Kenneth M, Alba Emilio, Pappas Lisa, Davis Carole A, Aranda Ignacio, Fauron Christiane, Stijleman Inge J, Palacios José, Antón Antonio, Carrasco Eva, Caballero Rosalía, Ellis Matthew J, Nielsen Torsten O, Perou Charles M, Astill Mark, Bernard Philip S, and Martín Miguel

Subjects
Internal medicine, RC31-1245, Genetics, QH426-470
Abstract

Abstract Background Many methodologies have been used in research to identify the “intrinsic” subtypes of breast cancer commonly known as Luminal A, Luminal B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often used for gene expression-based subtyping; however, surrogate subtyping using panels of immunohistochemical (IHC) markers are still widely used clinically. Discrepancies between these methods may lead to different treatment decisions. Methods We used the PAM50 RT-qPCR assay to expression profile 814 tumors from the GEICAM/9906 phase III clinical trial that enrolled women with locally advanced primary invasive breast cancer. All samples were scored at a single site by IHC for estrogen receptor (ER), progesterone receptor (PR), and Her2/neu (HER2) protein expression. Equivocal HER2 cases were confirmed by chromogenic in situ hybridization (CISH). Single gene scores by IHC/CISH were compared with RT-qPCR continuous gene expression values and “intrinsic” subtype assignment by the PAM50. High, medium, and low expression for ESR1, PGR, ERBB2, and proliferation were selected using quartile cut-points from the continuous RT-qPCR data across the PAM50 subtype assignments. Results ESR1, PGR, and ERBB2 gene expression had high agreement with established binary IHC cut-points (area under the curve (AUC) ≥ 0.9). Estrogen receptor positivity by IHC was strongly associated with Luminal (A and B) subtypes (92%), but only 75% of ER negative tumors were classified into the HER2-E and Basal-like subtypes. Luminal A tumors more frequently expressed PR than Luminal B (94% vs 74%) and Luminal A tumors were less likely to have high proliferation (11% vs 77%). Seventy-seven percent (30/39) of ER-/HER2+ tumors by IHC were classified as the HER2-E subtype. Triple negative tumors were mainly comprised of Basal-like (57%) and HER2-E (30%) subtypes. Single gene scoring for ESR1, PGR, and ERBB2 was more prognostic than the corresponding IHC markers as shown in a multivariate analysis. Conclusions The standard immunohistochemical panel for breast cancer (ER, PR, and HER2) does not adequately identify the PAM50 gene expression subtypes. Although there is high agreement between biomarker scoring by protein immunohistochemistry and gene expression, the gene expression determinations for ESR1 and ERBB2 status was more prognostic.

Published
2012
Full Text
View/download PDF

30. Is the molecular study of pituitary transcription factors useful in the identification of Pituitary Neuroendocrine Tumor subtypes according to the new WHO 2017 criteria?

Author

Garcia-Martinez, Araceli, primary, Martinez-Lopez, Sebastian, additional, Torregrosa, Maria Eugenia, additional, Silva, Sandra, additional, Fajardo, Carmen, additional, Camara, Rosa, additional, Lamas, Cristina, additional, Aranda, Ignacio, additional, and Pico, Antonio, additional

Published
2019
Full Text
View/download PDF

31. Epigenetic regulation by miRNAs in corticotroph tumors

Author

Garcia-Martinez, Araceli, primary, Lopez-Munoz, Beatriz, additional, Fajardo, Carmen, additional, Camara, Rosa, additional, Lamas, Cristina, additional, Torregrosa, Maria Eugenia, additional, Aranda, Ignacio, additional, and Pico, Antonio, additional

Published
2019
Full Text
View/download PDF

32. Silent somatotroph tumors

Author

Garcia-Martinez, Araceli, primary, Lloret, Adriana, additional, Torregrosa, Maria Eugenia, additional, Silva, Sandra, additional, Lamas, Cristina, additional, Fajardo, Carmen, additional, Camara, Rosa, additional, Aranda, Ignacio, additional, and Pico, Antonio, additional

Published
2019
Full Text
View/download PDF

35. RETFusion Testing in Patients With NSCLC: The RETING Study

Author

Conde, Esther, Hernandez, Susana, Rodriguez Carrillo, Jose Luis, Martinez, Rebeca, Alonso, Marta, Curto, Daniel, Jimenez, Beatriz, Caminoa, Alejandra, Benito, Amparo, Garrido, Pilar, Clave, Sergi, Arriola, Edurne, Esteban-Rodriguez, Isabel, De Castro, Javier, Sansano, Irene, Felip, Enriqueta, Rojo, Federico, Dómine, Manuel, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Teixido, Cristina, Reguart, Noemi, Compañ, Desamparados, Insa, Amelia, Mancheño, Nuria, Palanca, Sarai, Juan-Vidal, Oscar, Baixeras, Nuria, Nadal, Ernest, Cebollero, Maria, Calles, Antonio, Martin, Paloma, Salas, Clara, Provencio, Mariano, Aranda, Ignacio, Massuti, Bartomeu, Lopez-Vilaro, Laura, Majem, Margarita, Paz-Ares, Luis, and Lopez-Rios, Fernando

Abstract

RETinhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RETfusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect RETfusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC.

Published
2024
Full Text
View/download PDF

38. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

Author

Conde, Esther, Hernandez, Susana, Martinez, Rebeca, Angulo, Barbara, De Castro, Javier, Collazo-Lorduy, Ana, Jimenez, Beatriz, Muriel, Alfonso, Mate, Jose Luis, Moran, Teresa, Aranda, Ignacio, Massuti, Bartomeu, Rojo, Federico, Domine, Manuel, Sansano, Irene, Garcia, Felip, Felip, Enriqueta, Mancheño, Nuria, Juan, Oscar, Sanz, Julian, Gonzalez-Larriba, Jose Luis, Atienza-Cuevas, Lidia, Arriola-Arellano, Esperanza, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Camacho, Carmen, Rodriguez-Abreu, Delvys, Teixido, Cristina, Reguart, Noemi, Gonzalez-Piñeiro, Ana, Lazaro-Quintela, Martin, Lozano, Maria Dolores, Gurpide, Alfonso, Gomez-Roman, Javier, Lopez-Brea, Marta, Pijuan, Lara, Salido, Marta, Arriola, Edurne, Company, Amparo, Insa, Amelia, Esteban-Rodriguez, Isabel, Saiz, Monica, Azkona, Eider, Alvarez, Ramiro, Artal, Angel, Plaza, Maria Luz, Aguiar, David, Enguita, Ana Belen, Benito, Amparo, Paz-Ares, Luis, Garrido, Pilar, and Lopez-Rios, Fernando

Abstract

The ROS1gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. We have evaluated a novel anti-ROS1 IHC antibody (SP384) in a large multicenter series to obtain real-world data.

Published
2019
Full Text
View/download PDF

39. Malignant lymphoma in a patient with relapsing bronchiolitis obliterans organizing pneumonia

Author

Romero, Santiago, Martin, Concepcion, Massuti, Bartomeu, Aranda, Ignacio, and Hernandez, Luis

Subjects
Bacterial pneumonia -- Complications and side effects, Lymphomas -- Causes of -- Complications and side effects, Bronchiolitis -- Complications and side effects, Pneumonia -- Complications and side effects, Health, Complications and side effects, Causes of
Abstract

A case of relapsing bronchiolitis obliterans organizing pneumonia complicated by malignant lymphoma (four years after the diagnosis) is reported in a 58-year-old woman. To our knowledge, such an association has not been described previously in detail in the literature. (Chest 1992; 102:1895-97), BOOP = bronchiolitis obliterans organizing pneumonia; CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone; EBV = Epstein-Barr virus; HTLV = human T-cell lymphotropic virus; NHL = non-Hodgkin's lymphoma; TBB = transbronchial [...]

Published
1992

40. Lymphangitic Carcinomatosis as a Cause of Malignant Transient Pleural Transudate

Author

Garcia Sevila, Raquel, Barroso, Encarnacion, Martin, Concepcion, Aranda, Ignacio, and Romero, Santiago

Subjects
Article Subject
Abstract

Although it is generally accepted that a malignant transient pleural transudate may appear during the early stages of lymphatic obstruction, cases demonstrating such probability are rare in literature. A 67-year-old woman was admitted to hospital because a lymphangitic carcinomatosis and a transudative infrapulmonary pleural effusion with a cytology positive for adenocarcinoma. One month later the effusion keeps being positive for adenocarcinoma but exudative in character. Lymphatic obstruction appears as the cause of the initial transudative characteristics of the pleural effusion.

Published
2009
Full Text
View/download PDF

42. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers

Author

Bastien, Roy R. L., Rodríguez-Lescure, Álvaro, Ebbert, Mark T.W., Prat, Aleix, Munárriz, Blanca, Rowe, Leslie, Miller, Patricia, Ruiz Borrego, Manuel, Anderson, Daniel, Lyons, Bradley, Álvarez, Isabel, Dowell, Tracy, Wall, David, Seguí, Miguel Ángel, Barley, Lee, Boucher, Kenneth M., Alba, Emilio, Pappas, Lisa, Davis, Carole A., Aranda, Ignacio, Fauron, Christiane, Stijleman, Inge J., Palacios, José, Antón, Antonio, Carrasco, Eva, Caballero, Rosalía, Ellis, Matthew J., Nielsen, Torsten O., Perou, Charles M., Astill, Mark, Bernard, Philip S., Martín, Miguel, Bastien, Roy R. L., Rodríguez-Lescure, Álvaro, Ebbert, Mark T.W., Prat, Aleix, Munárriz, Blanca, Rowe, Leslie, Miller, Patricia, Ruiz Borrego, Manuel, Anderson, Daniel, Lyons, Bradley, Álvarez, Isabel, Dowell, Tracy, Wall, David, Seguí, Miguel Ángel, Barley, Lee, Boucher, Kenneth M., Alba, Emilio, Pappas, Lisa, Davis, Carole A., Aranda, Ignacio, Fauron, Christiane, Stijleman, Inge J., Palacios, José, Antón, Antonio, Carrasco, Eva, Caballero, Rosalía, Ellis, Matthew J., Nielsen, Torsten O., Perou, Charles M., Astill, Mark, Bernard, Philip S., and Martín, Miguel

Abstract

Background: Many methodologies have been used in research to identify the "intrinsic" subtypes of breast cancer commonly known as Luminal A, Luminal B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often used for gene expression-based subtyping; however, surrogate subtyping using panels of immunohistochemical (IHC) markers are still widely used clinically. Discrepancies between these methods may lead to different treatment decisions. Methods: We used the PAM50 RT-qPCR assay to expression profile 814 tumors from the GEICAM/9906 phase III clinical trial that enrolled women with locally advanced primary invasive breast cancer. All samples were scored at a single site by IHC for estrogen receptor (ER), progesterone receptor (PR), and Her2/neu (HER2) protein expression. Equivocal HER2 cases were confirmed by chromogenic in situ hybridization (CISH). Single gene scores by IHC/CISH were compared with RT-qPCR continuous gene expression values and "intrinsic" subtype assignment by the PAM50. High, medium, and low expression for ESR1, PGR, ERBB2, and proliferation were selected using quartile cut-points from the continuous RT-qPCR data across the PAM50 subtype assignments. Results: ESR1, PGR, and ERBB2 gene expression had high agreement with established binary IHC cut-points (area under the curve (AUC) ≥ 0.9). Estrogen receptor positivity by IHC was strongly associated with Luminal (A and B) subtypes (92%), but only 75% of ER negative tumors were classified into the HER2-E and Basal-like subtypes. Luminal A tumors more frequently expressed PR than Luminal B (94% vs 74%) and Luminal A tumors were less likely to have high proliferation (11% vs 77%). Seventy-seven percent (30/39) of ER-/HER2+ tumors by IHC were classified as the HER2-E subtype. Triple negative tumors were mainly comprised of Basal-like (57%) and HER2-E (30%) subtypes. Single gene scoring for ESR1, PGR, and ERBB2 was more prognostic than the corresponding IHC markers as shown in a multivariate anal

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results